A decade in to Andy Plump’s overhaul of Takeda’s R&D strategy, the plan is still evolving. Before Plump joined Takeda, the company was a small-molecule-focused organization. Plump and his ...

Psychiatric drug developers have for years been pointing to kappa-opioid receptor (KOR) antagonists as the poster children for a new era in psychiatric medicine. These drugs are thought to ...